Conrad Fischer

11PUBLICATIONS
24CO-AUTHORS
Proteins and peptidesPharmacogenomicsAnimal protection (incl. pests and pathogens)Molecular medicineBiological adaptation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 16, 2026
2-Substituted oxazolyl and thiazolyl amino acids are suitable P1 surrogates for new SARS-CoV-2 main protease inhibitors.

|Dec 22, 2025
Screening apelin analogues and a small molecule agonist as effective cardiovascular therapeutics against reperfusion injury.

Anjalee Wijewardane, Kleinberg X Fernandez, Anran Zhang

|Aug 18, 2025
Structural insights into the nirmatrelvir-resistant SARS-CoV-2 Mpro L50F/E166A/L167F triple mutant-inhibitor-complex reveal strategies for next generation coronaviral inhibitor design.

Conrad Fischer, Jimmy Lu, Marco J van Belkum

|Nov 20, 2024
Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease.

Jenson R Feys, Kyle Edwards, Michael A Joyce

|Nov 06, 2024
Assessment of optimized FRET substrates as universal corona- and picornavirus main protease substrates for screening assays.

Conrad Fischer, Tayla J Van Oers, Marco J van Belkum

|Aug 30, 2024
A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (Mpro) of SARS-CoV-2 and MERS-CoV.

Pu Chen, Tayla J Van Oers, Elena Arutyunova

Pageof 2

Frequent Collaborators

9 joint publications

John C Vederas

5 joint publications

M Joanne Lemieux

5 joint publications

Tess Lamer

5 joint publications

Marco J van Belkum